Clinical TrialJun 3, 2026, 08:01 AM
NewAmsterdam Pharma to Present Obicetrapib Data at NLA 2026 Sessions
AI Summary
NewAmsterdam Pharma announced it will present data on obicetrapib, its oral, non-statin medicine for cardiovascular disease, at the National Lipid Association (NLA) 2026 Scientific Sessions from June 11-14, 2026. The presentations will highlight obicetrapib's potential as a novel therapy for hypercholesterolemia, covering safety, efficacy, and impact on kidney function from various clinical trials. The company is developing obicetrapib to address limitations of current LDL-lowering treatments.
Key Highlights
- NewAmsterdam Pharma to present data on obicetrapib at the National Lipid Association (NLA) 2026 Scientific Sessions.
- Presentations will highlight obicetrapib's potential as a novel, oral, low-dose therapy for hypercholesterolemia.
- Data includes an integrated Phase III safety analysis of obicetrapib.
- Results from the BROADWAY trial show obicetrapib preserved kidney function in high cardiovascular risk patients.
- Pharmacokinetics and safety of obicetrapib in moderate hepatic impairment from Phase I study will be presented.
- Obicetrapib CETP inhibition remodels HDL2 and raises ApoM, S1P, ApoA1 monomers.
- Additional presentations cover statin intolerance, adverse events, and suboptimal adherence in real-world practice.
Price Impact
More from NAMS